ClinicalTrials.gg
Not yet recruitingNCT07469202Updated Nov 9, 2026

CYTALUX Dose Extension Study

A Phase 4 interventional study of CYTALUX (pafolacianine) injection in Cancer in the Lung and Ovarian Cancer, sponsored by On Target Laboratories, LLC. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by On Target Laboratories, LLC · Phase 4, Interventional, and Diagnostic

Updated Nov 9, 2026Start date movedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
106
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this clinical trial is to learn whether giving Cytalux™ (pafolacianine) injection several days before surgery works as well as giving it closer to the time of surgery for helping surgeons see lesions during an operation. This study is being done in adult patients undergoing surgery for malignant or non-malignant lung lesions or for confirmed ovarian cancer.

Read the detailed description

This is a prospective, multicenter, open-label, non-inferiority study designed to evaluate the clinical adequacy of intraoperative tumor fluorescence following administration of Cytalux™ (pafolacianine) injection at two different administration time windows in adult subjects undergoing surgery for known or suspected cancer in the lung or ovarian cancer.

The study will enroll adult patients with either malignant or non-malignant lung lesions with known or suspected lung cancer, or patients with a confirmed diagnosis of ovarian cancer, who are scheduled to undergo surgical resection. Cytalux™ (pafolacianine) injection is an FDA-approved optical imaging agent indicated as an adjunct for intraoperative identification of malignant and non-malignant pulmonary lesions in adults with known or suspected lung cancer, and for malignant lesions in adults with ovarian cancer.

Eligible participants will receive a single intravenous dose of Cytalux™ at the FDA-approved dose of 0.025 mg/kg. The dose level will remain consistent with the approved labeling. Participants will be assigned to one of two dosing windows.

During surgery, intraoperative molecular imaging will be performed to assess tumor fluorescence following administration of Cytalux™.

The primary objective of the study is to demonstrate non-inferiority of Cytalux™ administration within an extended dosing window of 120-168 hours prior to surgery compared with the currently approved administration windows (lung: 1-24 hours; ovarian: 1-9 hours).

02

Conditions studied

  • Cancer in the Lung
  • Ovarian Cancer

Keywords

  • cancer in the lung
  • lung cancer
  • ovarian cancer
  • lung cancer surgery
  • ovarian cancer surgery
  • CYTALUX
  • pafolacianine
  • fluorescent
  • molecular imaging
03

In context

Ovarian Neoplasms

3,389 studies on the registry are indexed under Ovarian Neoplasms; 791 are open to participants now.

This study's planned enrollment of 106 is above the median of 54 across 2,553 interventional studies indexed under Ovarian Neoplasms.

Browse Ovarian Neoplasms studies →

Lead sponsor

On Target Laboratories, LLC is the lead sponsor of 5 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male and female patients 18 years of age and older
  2. Primary diagnosis, or a high clinical suspicion, of cancer in the lung warranting surgery based on CT/PET or other imaging obtained within 4 months of the screening visit, or have a primary diagnosis for ovarian cancer
  3. Scheduled to undergo surgical thoracoscopy for wedge resection or anatomic lung resection, or ovarian cancer debulking/cytoreduction
  4. Willingness of research participant or legal guardian/representative to give written

Exclusion criteria

Exclusion Criteria:

  1. History of anaphylactic reactions to products containing indocyanine green for near infrared imaging. Subjects with a medical history of 'idiopathic anaphylaxis' will require evaluation.
  2. History of allergy to any of the components of Cytalux™ (pafolacianine)
  3. Presence of any psychological, familial, sociological condition or geographical challenges potentially hampering compliance with the study protocol or follow-up schedule
  4. Known sensitivity to fluorescent light
  5. Impaired renal function defined as \< 50 mL/min/1.73m2
  6. Impaired liver function defined as values > 3x the (ULN) for (ALT) or aspartate aminotransferase (AST), alkaline phosphatase (ALP), or >2x ULN for total excluding those patients with Gilbert's syndrome
  7. Pregnant and/or lactating women
  8. Administration of folate, folic acid, or folate-containing supplements 48 hours before administration of Cytalux™ (pafolacianine)
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Phase 4
Primary purpose
Diagnostic
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
106 participants (estimated)

Study arms

  • Active comparator
    Lung dosing 1-24 hours prior to imaging

    Subjects with malignant and non-malignant lesions in the lung dosed with CYTALUX (0.025 mg/kg) 1-24 hours prior to imaging

    Drug: CYTALUX (pafolacianine) injection

  • Experimental
    Lung dosing 120-168 hours prior to imaging

    Subjects with malignant and non-malignant lesions in the lung dosed with CYTALUX (0.025 mg/kg) 120-168 hours prior to imaging

    Drug: CYTALUX (pafolacianine) injection

  • Active comparator
    Ovarian dosing 1-9 hours prior to imaging

    Subjects with ovarian cancer dosed with CYTALUX (0.025 mg/kg) 1-9 hours prior to imaging

    Drug: CYTALUX (pafolacianine) injection

  • Experimental
    Ovarian dosing 120-168 hours prior to imaging

    Subjects with ovarian cancer dosed with CYTALUX (0.025 mg/kg) 120-168 hours prior to imaging

    Drug: CYTALUX (pafolacianine) injection

Interventions

  • CYTALUX™ (PAFOLACIANINE) INJECTION: folate analog ligand conjugated with an indole cyanine green-like dye. Each subject will be administered a single intravenous dose (0.025 mg/kg) based on their assigned cohort before initiation of intraoperative NIR fluorescent imaging

    Also known as: pafolacianine injection

06

What researchers measure

Primary outcomes

  1. Tumor-to-background ratio

    Mean difference in in-situ tumor-to-background ratio (TBR) between 120-168 hours and the approved window

    Time frame: 1 day

Secondary outcomes

  1. Sensitivity

    The sensitivity of Cytalux™ (pafolacianine) with NIR imaging for detection of malignant and non-malignant lung lesions and malignant ovarian cancer lesions. The sensitivity is defined as the proportion of fluorescent light positive lesions that are histologically confirmed to be cancer relative to the total number of lesions confirmed to be cancer.

    Time frame: 1 day

  2. Sensitivity of folate receptor-positive lesions

    The sensitivity of Cytalux with NIR imaging for detection of malignant and non-malignant lung lesions and for malignant ovarian cancer lesions that are confirmed to be folate receptor alpha and/or folate receptor beta positive

    Time frame: 1 day

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Tanyi JL, Randall LM, Chambers SK, Butler KA, Winer IS, Langstraat CL, Han ES, Vahrmeijer AL, Chon HS, Morgan MA, Powell MA, Tseng JH, Lopez AS, Wenham RM. A Phase III Study of Pafolacianine Injection (OTL38) for Intraoperative Imaging of Folate Receptor-Positive Ovarian Cancer (Study 006). J Clin Oncol. 2023 Jan 10;41(2):276-284. doi: 10.1200/JCO.22.00291. Epub 2022 Sep 7. PubMed 36070540 ↗
  • Sarkaria IS, Martin LW, Rice DC, Blackmon SH, Slade HB, Singhal S; ELUCIDATE Study Group. Pafolacianine for intraoperative molecular imaging of cancer in the lung: The ELUCIDATE trial. J Thorac Cardiovasc Surg. 2023 Dec;166(6):e468-e478. doi: 10.1016/j.jtcvs.2023.02.025. Epub 2023 Mar 3. PubMed 37019717 ↗

Related links

Individual participant data

Plan to share: No — Information is not relevant to other researchers

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Start is estimated for Nov 2026; primary completion for May 2027, 6 months later.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 9, 2026: start Aug 2026 → Nov 2026, primary completion Feb 2027 → May 2027 and completion Feb 2027 → May 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 9, 2026
First posted
Mar 13, 2026
StartEst.
Nov 15, 2026was Aug 2026
Primary completionEst.
May 28, 2027was Feb 2027
CompletionEst.
May 28, 2027was Feb 2027
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Aug 15, 2026→Nov 15, 2026
Nov 9, 2026
Primary completion
Feb 28, 2027→May 28, 2027
Nov 9, 2026
Study completion
Feb 28, 2027→May 28, 2027
Nov 9, 2026
Show all 1 update
  1. Nov 9, 2026
    Start date Aug 15, 2026→Nov 15, 2026
    Primary completion Feb 28, 2027→May 28, 2027
    Study completion Feb 28, 2027→May 28, 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07469202
Lead sponsor
On Target Laboratories, LLC
Responsible party
Sponsor
First posted
Mar 13, 2026
Start date
Nov 15, 2026 (estimated)
Primary completion
May 28, 2027 (estimated)
Completion
May 28, 2027 (estimated)
Last update
Nov 9, 2026

Study contacts

Tina Barrett
Contact
tbarrett@ontargetlabs.com
765-588-4547

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pafolacianine

Start the discussion